BC Week In Review | Oct 18, 2004
Clinical News

Cerovive: Phase III ongoing

An independent data monitoring committee recommended continuation of the SAINT I and SAINT II Phase III trials. AZN licensed the compound from Centaur Pharmaceuticals Inc. , which RNVS acquired in 2002. Renovis Inc. (RNVS), South San...
BC Week In Review | Jun 2, 2003
Clinical News

Cerovive: Phase III

AZN began the SAINT I and SAINT II international, double-blind Phase III trials. The trials will compare a 72-hour intravenous infusion of Cerovive given within 6 hours of the onset of symptoms to placebo in...
BC Week In Review | Nov 4, 2002
Company News

Centaur, CV Tech deal

CVQ and Centaur started a joint venture called Vet Ex Inc. (Alberta, Edmonton). Vet Ex has received exclusive worldwide veterinary rights for CVQ’s ChemBioPrint nutraceutical discovery technology and existing nutraceutical leads. Centaur Pharmaceuticals Inc. , Sunnyvale,...
BC Week In Review | Sep 9, 2002
Company News

OxoN management update

OxoN Medica Inc. , South San Francisco, Calif.   Business: Cardiovascular, Metabolic, Pulmonary   Hired: Paul Wood as CEO and president, formerly president and CEO of Centaur Pharmaceuticals Inc.  ...
BC Week In Review | Mar 25, 2002
Company News

GB Therapeutics board of directors update

GB Therapeutics, Kingston, Ontario   Business: Cardiovascular, Neurological   Appointed: John Molloy, president and CEO of Parteq Innovations, as chairman; Ian Anderson, president and CEO; James Reynolds, VP of biological sciences; Jean-Paul St. Pierre, physician;...
BioCentury | May 7, 2001
Finance

VCs rediscover neurology

While the industry may be relieved to see venture capital continue to pour into biotech, few may be noticing that companies working in neurological disorders are suddenly getting a larger slice of the pie. After...
BC Week In Review | Mar 5, 2001
Clinical News

Centaur preclinical data

Researchers published in Stroke that NXY-059 lessened disability in an primate model of stroke. The product, which is in Phase II testing, is partnered with AstraZeneca plc (LSE:AZN; AZN, London, U.K.). Centaur Pharmaceuticals Inc., Sunnyvale,...
BC Week In Review | Jan 29, 2001
Company News

Centaur management update

Centaur Pharmaceuticals Inc. , Sunnyvale, Calif.   Business: Neurological   Hired: Dushyant Pathak as SVP of business development and strategic planning, formerly president and CEO of BioProtocol Inc.; and Philip James as VP of clinical development,...
BC Week In Review | Dec 4, 2000
Clinical News

NXY-059: Began Phase I testing

Centaur Pharmaceuticals Inc., Sunnyvale, Calif.   Product: NXY-059   Business: Neurological   Therapeutic category: Neuroprotectant   Target: Neurons   Description: Intravenous neuroprotectant   Indication: Treat acute stroke   Status: Partner AstraZeneca plc (LSE:AZN; AZN, London,...
BC Week In Review | Oct 23, 2000
Clinical News

CPI-1189: Phase IIa

Interim results from Centaur's U.S. Phase IIa trial in 64 HIV infected patients with AIDS dementia showed that CPI-1189 was well tolerated, with >90 percent of CPI-1189-treated patients completing the 10-week blinded portion of the...
Items per page:
1 - 10 of 23
BC Week In Review | Oct 18, 2004
Clinical News

Cerovive: Phase III ongoing

An independent data monitoring committee recommended continuation of the SAINT I and SAINT II Phase III trials. AZN licensed the compound from Centaur Pharmaceuticals Inc. , which RNVS acquired in 2002. Renovis Inc. (RNVS), South San...
BC Week In Review | Jun 2, 2003
Clinical News

Cerovive: Phase III

AZN began the SAINT I and SAINT II international, double-blind Phase III trials. The trials will compare a 72-hour intravenous infusion of Cerovive given within 6 hours of the onset of symptoms to placebo in...
BC Week In Review | Nov 4, 2002
Company News

Centaur, CV Tech deal

CVQ and Centaur started a joint venture called Vet Ex Inc. (Alberta, Edmonton). Vet Ex has received exclusive worldwide veterinary rights for CVQ’s ChemBioPrint nutraceutical discovery technology and existing nutraceutical leads. Centaur Pharmaceuticals Inc. , Sunnyvale,...
BC Week In Review | Sep 9, 2002
Company News

OxoN management update

OxoN Medica Inc. , South San Francisco, Calif.   Business: Cardiovascular, Metabolic, Pulmonary   Hired: Paul Wood as CEO and president, formerly president and CEO of Centaur Pharmaceuticals Inc.  ...
BC Week In Review | Mar 25, 2002
Company News

GB Therapeutics board of directors update

GB Therapeutics, Kingston, Ontario   Business: Cardiovascular, Neurological   Appointed: John Molloy, president and CEO of Parteq Innovations, as chairman; Ian Anderson, president and CEO; James Reynolds, VP of biological sciences; Jean-Paul St. Pierre, physician;...
BioCentury | May 7, 2001
Finance

VCs rediscover neurology

While the industry may be relieved to see venture capital continue to pour into biotech, few may be noticing that companies working in neurological disorders are suddenly getting a larger slice of the pie. After...
BC Week In Review | Mar 5, 2001
Clinical News

Centaur preclinical data

Researchers published in Stroke that NXY-059 lessened disability in an primate model of stroke. The product, which is in Phase II testing, is partnered with AstraZeneca plc (LSE:AZN; AZN, London, U.K.). Centaur Pharmaceuticals Inc., Sunnyvale,...
BC Week In Review | Jan 29, 2001
Company News

Centaur management update

Centaur Pharmaceuticals Inc. , Sunnyvale, Calif.   Business: Neurological   Hired: Dushyant Pathak as SVP of business development and strategic planning, formerly president and CEO of BioProtocol Inc.; and Philip James as VP of clinical development,...
BC Week In Review | Dec 4, 2000
Clinical News

NXY-059: Began Phase I testing

Centaur Pharmaceuticals Inc., Sunnyvale, Calif.   Product: NXY-059   Business: Neurological   Therapeutic category: Neuroprotectant   Target: Neurons   Description: Intravenous neuroprotectant   Indication: Treat acute stroke   Status: Partner AstraZeneca plc (LSE:AZN; AZN, London,...
BC Week In Review | Oct 23, 2000
Clinical News

CPI-1189: Phase IIa

Interim results from Centaur's U.S. Phase IIa trial in 64 HIV infected patients with AIDS dementia showed that CPI-1189 was well tolerated, with >90 percent of CPI-1189-treated patients completing the 10-week blinded portion of the...
Items per page:
1 - 10 of 23